On Cancer: Immunotherapy

Share
Print
and/or
91 Blog posts found

In the News

Updates from SABCS 2019: Detection and Screening, Immunotherapy Advances, and Therapy Resistance

About two dozen MSK physicians and researchers shared their work at the world’s leading breast cancer conference, held annually in San Antonio.

A presentation stage at the San Antonio Breast Cancer Symposium.

In the Lab

Newly Discovered Immune Cell Subtypes Could Shake Up Immunotherapy

Dendritic cells, the guards of the immune system, have a previously unrecognized division of labor.

a colorful dendritic cell

In the Clinic

6 Breakthroughs That Are Changing Chemotherapy for People with Breast Cancer

Discover some of the latest innovations in chemotherapy for breast cancer.

MSK patient receiving chemotherapy

In the Clinic

5 Reasons MSK Excels at Treating Gynecologic Cancers

Read why MSK’s medical team is the best in the nation at treating gynecologic cancers.

Memorial Sloan Kettering surgeons Oliver Zivanovic, Kara Long Roche, Ginger Gardner, and Yukio Sonoda

In the Clinic

Prestigious Grant Bolsters Bladder Cancer Research at MSK

A prominent research grant will enable MSK doctors and scientists to advance the treatment of bladder cancer.

Conceptual orange-and-green-colored X-ray showing cancer of the bladder.

Finding

One Patient’s Exceptional Response Leads to a Surprising Discovery about Immunotherapy

MSK researchers learn that some cancers may respond to checkpoint inhibitor drugs because of changes called gene fusions.

Drawing of one human figure set apart from a group of others.

In the Clinic

CAR Therapy for Solid Tumors Draws Attention at Annual Cancer Conference

Results from a clinical trial indicate that an experimental CAR therapy for mesothelioma is safe.

Scientific Image

Q&A

Gut Check: What You Need to Know about a Common Side Effect of Immunotherapy

Learn about gastrointestinal distress, one of the more common side effects of immunotherapy.

A man clutches his stomach in pain

Finding

Tumor Mutational Burden Can Help Predict Response to Immunotherapy in Many Different Cancers

Investigators confirmed that people whose tumors have a high tumor mutational burden and were treated with immunotherapy lived longer.

Tumor mutation model